leisure time -WSS

leisure time

author：fashion 2025-09-29 19:06:42 - browse：82822

Seng Cheng has been working in gene therapy for nearly as long as gene therapy has been a field. As a young scientist in the early 1990s, he was part of one of three teams racing to develop a gene therapy for cystic fibrosis, a high-profile effort that resulted in national headlines, prestigious publications, and zero patients cured.

So he’s seen the field’s highs and lows. Lately, there have been a lot of both, including at Pfizer, the company Cheng called home until this summer. The pharma brought three potentially powerful gene therapies for muscular dystrophy and hemophilia into late-stage trials but, in January, chose to abandon a large portfolio of early stage candidates that relied on the same technology: adeno-associated viruses, or AAVs, a group of small bugs that scientists spent two decades taming into a gene shipping system.

The move seemed emblematic. Across the industry, AAV companies have been struggling, either shelving programs or stopping work altogether, while investors shuttled money toward new technologies such as CRISPR and its various permutations. Longtime researchers feared promising drugs, particularly for ultra-rare diseases, might get lost in the shuffle.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： DeSantis can now import cheaper drugs. But will Biden get credit?

focus

WSS

As JPM 2024 winds down, some health tech firms project optimism

Elisabeth Bik tackles the widespread issue of research misconduct

GSK to buy asthma

Covid overtakes 1918 Spanish flu as deadliest disease in U.S. history

Medicare isn't yet testing food as medicine

Doctor of U.S. President Joe Biden says he is fit for duty

entertainment

leisure time

explore

How one medical school became remarkably diverse

New menopause drug shows promise in relief for hot flashes

Drug repurposing or repositioning? The language matters

Color Health wants to make cancer screenings convenient

Trump demands the U.S. pay no more for drugs than other countries … again

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

Sports medicine is finally prioritizing gender equality

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

hotspot

How I ended up pumping milk in a bathroom stall at JPM 2024

Medicare isn't yet testing food as medicine

New Medicare drug pricing powers could soon be upended in court

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

The nurse manager staffing crisis is hurting patients

JPM 2024: Nvidia claims we're in biological revolution. Are we?

entertainment

leisure time

focus

entertainment